BACK

Preprint looking at immune response after a first dose of the Pfizer vaccine in those with and without prior infection with SARS-CoV-2

This article was published on
March 26, 2021

This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.

A preprint, an unpublished non-peer reviewed study, looks at the T-cell and antibody respondes to the first dose of Pfizer-BioNTech COVID-19 vaccine in previously infected and infection-naïve UK healthcare workers.

A preprint, an unpublished non-peer reviewed study, looks at the T-cell and antibody respondes to the first dose of Pfizer-BioNTech COVID-19 vaccine in previously infected and infection-naïve UK healthcare workers.

Publication

T-cell and antibody responses to first BNT162b2 vaccine dose in previously SARS-CoV-2-infected and infection-naive UK healthcare workers: a multicentre, prospective, observational cohort study

Not peer-reviewed
This work has not been scrutinised by independent experts, or the story does not contain research data to review (for example an opinion piece). If you are reporting on research that has yet to go through peer-review (eg. conference abstracts and preprints) be aware that the findings can change during the peer review process
Peer-reviewed
This work was reviewed and scrutinised by relevant independent experts.

What our experts say

Context and background

Resources

Media briefing

Media Release

Expert Comments: 

Prof Eleanor Riley

This large, well-controlled study of UK health care workers demonstrates that a single dose of the Pfizer BioNtech COVID-19 vaccine induces antibody and T cell responses comparable to those seen after natural infection. As natural infection has been shown to confer greater than 80% protection against reinfection, these data offer considerable reassurance that JCVI’s somewhat controversial decision to recommend a 12 week interval between COVID-19 vaccine doses is a safe, effective and pragmatic approach to maximising public health given current constraints.

Importantly, this study shows that vaccination of previously infected individuals not only boosts their immune responses but also broadens the repertoire of immune responses to SARS-CoV-2 and, in so doing, enhances the response to several variants of concern including the so-called Kent, South African and Brazilian variants. These data demonstrate the importance of vaccinating everyone, including people who have already been infected.

A single dose of vaccine in uninfected individuals also induces neutralising antibodies to the variants of concern, although at much lower levels. It remains to be seen whether these antibodies can be enhanced after a second dose of the current vaccine or whether a further boost – possibly with a second generation, variant-specific vaccine – might be needed.

Prof Daniel Altmann

This interesting study adds to the existing body of work from antibody studies, now showing that both antibodies and also T cell responses show a considerable boost in people who have had their first dose of Pfizer vaccine, having been previously primed through natural infection with the virus. Responses are extremely high – higher than seen for the conventional situation of two vaccine doses without prior infection. Of course, findings such as this have inevitably led to debate about whether vaccine supplies could be stretched further by offering only a single dose to those known to have been previously infected. For most of the world, including the UK, there may be sufficient diagnostic uncertainty as to who was definitely infected to make this approach hard to implement efficiently.

Q&A

No items found.